CMCSA three-lens brief
Evidence-based stock research on CMCSA. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Underperforming SPY by 18.3pp over 30 days. · Debt-to-equity of 106.9 — balance-sheet-heavy.
- Underperforming SPY by 18.3pp over 30 days.
- P/E of 5.3 — trading at a value multiple.
- Analyst mean target $32.98 — 22% above current (21 analysts).
- Debt-to-equity of 106.9 — balance-sheet-heavy.
CMCSA closed at $26.98 (-0.68%) as of 2026-05-04. Market cap: $96.38B. P/E (trailing) 5.3. Positives: p/E of 5.3 — trading at a value multiple.; analyst mean target $32.98 — 22% above current (21 analysts).. Concerns: underperforming SPY by 18.3pp over 30 days.; debt-to-equity of 106.9 — balance-sheet-heavy.. Last quarter: Revenue $31.46B, net income $2.17B, free cash flow $4.01B.
Why three lenses on CMCSA, not one.
A single reasoning model has blind spots it doesn’t know about. We examine CMCSAacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/CMCSA" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath CMCSA brief"></iframe>